Aap Implantate AG Financial Year 2025 Begins Steadily with EMEA Growth

aap Implantate AG has started 2025 on a stable note, with the EMEA region maintaining its position as the highest contributor to sales. In the first quarter, sales were comparable to last year, driven by new products with US FDA approval.

Overall turnover slightly decreased by 1% compared to Q1 2024. Notably, the EMEA region saw a 17% sales increase, while North America and LATAM regions faced declines. APAC experienced a modest 4% growth.

South Africa's performance stood out with a 60% rise in sales, and Germany achieved a 5% growth despite challenges in its hospital market. LATAM's performance was hindered by delayed budget approvals.

Looking ahead, the order backlog of approximately €160,000 portends a promising Q2. The company's antibacterial silver technology trial remains on course, with completion expected by August 2025, supported by BMBF funding. Upcoming CE market portfolio expansions signal positive growth prospects.